Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's Blood Products Advisory Cmte.

Executive Summary

Second day of Sept. 17-18 meeting will take place at Parklawn Building, Conference Rooms G & H, not at Office of Biologics Research, as was previously scheduled. First day will still take place at Office of Biologics Research, located on the NIH campus. Public portions of the meeting will discuss reevaluation methods for persons who are currently deferred from donating blood because of reactive hepatitis B surface antigen tests. Public sessions begin at 9:00 A.M. on Sept. 17 and 8:00 A.M. on Sept. 18.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS012442

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel